- Three new Takeda diabetes drugs become available
- Research Now launches diabetes panel
- Study: Type 2 diabetes market competition heats up amid disease rate increase
- Report: Sugar accounts for 17% of normal U.S. diet as Type 2 diabetes accounts for $500 billion in global healthcare spending
- Hamacher's Dave Wendland to moderate DSN Diabetes & Chronic Care Roundtable for 10th-consecutive year
MANCHESTER, N.H. — Boston Therapeutics is seeking approval for a generic version of a pill for Type 2 diabetes, the drug maker said.
Boston Therapeutics announced that it had filed an application with the Food and Drug Administration for chewable metformin tablets. The drug is a version of Bristol-Myers Squibb's Glucophage.
"Metformin is one of the most widely prescribed diabetes drugs in the world, and our neural chemistry polysaccharide formulation will benefit prediabetic and diabetic patients," Boston Therapeutics CEO David Platt said. "This new option in treatments fits into our pipeline of other diabetes therapeutics, including Ipoxyn for limb ischemia and PAZ-320 for blood glucose management."